Viatris offers a solid dividend yield of approximately 3.24% , which may appeal to income-focused investors.
Discounted Cash Flow (DCF) models suggest the stock is significantly undervalued, with some estimates placing "fair value" as high as $56.03 . mylan stock buy or sell
Mylan (formerly NASDAQ: MYL) no longer exists as an independent stock. In November 2020, Mylan merged with Pfizer’s Upjohn business to form a new company called (NASDAQ: VTRS ). Viatris offers a solid dividend yield of approximately 3
~$14.67, indicating a slight forecasted downside of roughly -1% . Target Range: High of $18.00 and a low of $10.00 . Investment Case: Buy vs. Sell Buy Case (Bullish) Sell/Hold Case (Bearish) In November 2020, Mylan merged with Pfizer’s Upjohn
AI responses may include mistakes. For financial advice, consult a professional. Learn more
The company expects 2026 to be a "pivotal year" with 2% revenue growth and $650 million in planned cost savings.
Analysts are concerned about a lack of a clear growth strategy following an EBITDA "trough" expected in 2025 due to manufacturing issues.